IP方案化疗对小细胞肺癌患者血清VEGF及内皮抑素的影响

目的 探讨IP方案化疗对小细胞肺癌（SCLC）患者血清血管内皮生长因子（VEGF）及内皮抑素的影响.方法 对45例SCLC患者行IP方案化疗,采用ELISA法检测其化疗前后的血清VEGF、内皮抑素,同时对20例健康对照者进行比较.结果 SCLC患者的血清VEGF、内皮抑素均高于对照者（P均＜0.01）,二者水平与患者的年龄、性别、吸烟与否无关,与临床分期有关（P＜0.05）;临床受益患者化疗后血清VEGF下降、内皮抑素升高（P均＜0.01）;血清VEGF低于平均值组的中位生存期长于高于平均值组,内皮抑素高于平均值组中位生存期长于低于平均值组（P均＜0.05）.结论 SCLC患者血清VEGF及内皮抑素的变化对判定化疗疗效及预后有一定参考价值.

Effects of IP chemotherapy on the changes of serum VEGF and endostatin in patients with small-cell lung cancer

Objective To investigate the effects of IP chemotherapy on the changes of serum VEGF and endostatin in patients with small-cell lung cancer （SCLC）.Methods The serum VEGF and endostatin levels of 45 SCLC patients before chemotherapy and after being treated by IP chemotherapy were detected by ELISA,respectively.Meanwhile,the serum VEGF and endostatin levels of 20 healthy controls were detected and compared with those of 45 SCLC patients.Results The serum VEGF and endostatin levels of SCLC patients were significantly higher than those of the healthy controls （all P ＜0.01）,and the levels of SCLC patients were not correlated with age,sex and smoking,but correlated with stages （P ＜0.05）.The serum VEGF level of clinical benefit patients decreased significantly and the endostatin level increased significantly after chemotherapy （all P ＜ 0.01）.Median survival time in the patients whose serum VEGF level was lower than the average was longer than the patients whose level was higher than the average; median survival time in the patients whose serum endostatin level was higher than the average was longer than the patients whose level was lower than the average （all P ＜ 0.05）.Conclusion The changes of serum VEGF and endostatin levels are valuable for evaluating the curative effects and prognosis of chemotherapy.